Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 06/26–06/29 | 06/30 | 544,528 sh38 trades | $109.98avg. | $59,884,936.63 | −54.1% | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale | 06/26 | 06/26 | 1,630,658 sh4 trades | $106.50avg. | $173,665,077 | No record | |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 06/23–06/25 | 06/25 | 684,449 sh52 trades | $115.13avg. | $78,800,263.69 | −56.4% | |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 06/25 | 06/25 | 5,000 sh2 trades | $114.00avg. | $570,000 | −9.1% | |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 06/17–06/22 | 06/22 | 509,996 sh33 trades | $95.28avg. | $48,592,330.98 | No record | |
Noah GoodmanChief Business Officer | Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 06/22 | 06/22 | 2,500 sh | $99.00 | $247,500 | −4.7% |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 05/26–05/27 | 05/27 | 17,184 sh7 trades | $79.92avg. | $1,373,263.59 | −28.1% | |
Elena RidloffDirector | Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 05/11 | 05/11 | 3,000 sh | $87.00 | $261,000 | −100.0% |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 04/29 | 04/29 | 30,000 sh3 trades | $81.18avg. | $2,435,377.2 | −4.3% | |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 04/22 | 04/24 | 300 sh | $90.00 | $27,000 | −0.5% | |
Kymera TherapeuticsKYMR | Open-market sale10b5-1 plan | 04/22 | 04/24 | 6,000 sh3 trades | $89.96avg. | $539,772 | No record |